Hyperferritinemia as a tumor marker
- Authors: Topnikova Y.V.1, Nevzorova E.V.1
-
Affiliations:
- G.R. Derzhavin Tambov State University
- Issue: Vol 5, No 1 (2025)
- Pages: 38-46
- Section: NEW DIRECTIONS AND ADVANCEMENTS IN TREATMENT OF ONCOLOGICAL DISEASES IN THE CURRENT AGE
- Published: 05.03.2025
- URL: https://mdonco.abvpress.ru/jour/article/view/174
- DOI: https://doi.org/10.17650/2782-3202-2025-5-1-38-46
- ID: 174
Cite item
Full Text
Abstract
The level of serum ferritin is elevated in many malignant tumors. Ferritin concentration in serum should be considered a clinically useful tumor marker representing a significant and simple parameter for disease activity monitoring.
Aim of the work is to present a clinical case of a 74-year-old female patient with a diagnosis of “bone and lung metastases without primary tumor, stage IV, 2nd clinical group” (per the International Classification of Diseases 10th revision: С79.5. Secondary malignant neoplasm of bone and bone marrow), determine diagnostic and prognostic value of ferritin levels in some types of cancer.
Due to worsening condition in the form of increased fatigue, bone pain, food refusal, the patient sought a consultation with an oncologist and was referred for hospitalization in a therapy unit with the main diagnosis of “D50.9. Iron deficiency anemia, unspecified” and concomitant diagnosis of “Kaposi’s sarcoma of the skin?” Biochemical blood work showed high ferritin levels. The presented clinical case demonstrated high diagnostic and prognostic value of ferritin level as not only iron depot but also as an acute phase protein. It is known that aberrant ferritin expression is associated with various malignant neoplasms, and high ferritin levels accompany severe diseases. In the case of our patient, the increase in this parameter showed progression of oncological process.
About the authors
Yu. V. Topnikova
G.R. Derzhavin Tambov State University
Author for correspondence.
Email: yulia.smirno@mail.ru
ORCID iD: 0009-0005-4044-4938
Yuliya Viktorovna Topnikova
33 Internatsionalnaya St., Tambov 392036
Russian FederationE. V. Nevzorova
G.R. Derzhavin Tambov State University
ORCID iD: 0000-0003-3229-0738
33 Internatsionalnaya St., Tambov 392036
Russian FederationReferences
- Popandopulo A. Hyperferritinemia is an increased ferritin in the blood in cancer and other serious diseases. Available at: https://unclinic.ru/giperferritinemijapovyshennyjferritinvkroviprirakeidrugihtjazhelyhzabolevanijah/ (In Russ.).
- Jian N., Dowle M., Horniblow R.D. et al. Morphology of the ferritin iron core by aberration corrected scanning transmission electron microscopy. Nanotechnology 2016;27(46):46LT02. doi: 10.1088/09574484/27/46/46LT02
- Melino G., Stefanini S., Chiancone E., Antonini E. Stoichiometry of iron oxidation by apoferritin. FEBS Lett 1978;86(1):136–8. doi: 10.1016/00145793(78)80115x
- Cronin S.J.F., Woolf C.J., Weiss G., Penninger J.M. The role of iron regulation in immunometabolism and immunerelated disease. Front Mol Biosci 2019;6:116. doi: 10.3389/fmolb.2019.00116
- Conrad M., Pratt D.A. The chemical basis of ferroptosis. Nat Chem Biol 2019;15(12):1137–47. doi: 10.1038/s4158901904081
- Stockwell B.R., Friedmann Angeli J.P., Bayir H. et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 2017;171(2):273–85. doi: 10.1016/j.cell.2017.09.021
- Xie Y., Hou W., Song X. et al. Ferroptosis: process and function. Cell Death Differ 2016;23(3):369–79. doi: 10.1038/cdd.2015.158
- Knovich M.A., Storey J.A., Coffman L.G. et al. Ferritin for the clinician. Blood Rev 2009;23(3):95–104. doi: 10.1016/j.blre.2008.08.001
- Shi X., Zhang A., Lu J. et al. An overview of heavy chain ferritin in cancer. Front Biosci (Landmark Ed) 2023;28(8):182. doi: 10.31083/j.fbl2808182
- Zhuge X., Zhou H., Chen L. et al. The association between serum ferritin levels and malignant intraductal papillary mucinous neoplasms. BMC Cancer 2021;21:1253. doi: 10.1186/s1288502108986z
- Kirkali Z., Esen A.A., Kirkali G., Güner G. Ferritin: a tumor marker expressed by renal cell carcinoma. Eur Urol 1995;28(2):131–4. doi: 10.1159/000475037
- Tanaka M., Fernándezdel Castillo C., Adsay V. et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012;12(3):183–97. doi: 10.1016/j.pan.2012.04.004
- Friedrichs K.R., Thomas C., Plier M. et al. Evaluation of serum ferritin as a tumor marker for canine histiocytic sarcoma. J Vet Intern Med 2010;24(4):904–11. doi: 10.1111/j.19391676.2010.0543.x
- Engelmann U., Büber V., Riedmiller H., Jacobi G.H. Ferritin – another tumor marker for testicular malignancies. Eur Urol 1981;7(6):355–8. doi: 10.1159/000473264
- Aulbert E., Schmidt C.G. Ferritin. A tumor marker in myeloid leukemia. Cancer Detect Prev 1985;8(1–2):302.
Supplementary files

